AMPH 📈 Amphastar P - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03209R1032
AMPH: Insulin, Epinephrine, Anesthetics, Inhalers, Injectables, Nasal Sprays, Syringes
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Web URL: https://www.amphastar.com
Additional Sources for AMPH Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AMPH Stock Overview
Market Cap in USD | 2,174m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2014-06-25 |
AMPH Stock Ratings
Growth 5y | 54.6% |
Fundamental | 84.3% |
Dividend | - |
Rel. Strength Industry | -744 |
Analysts | 3.8/5 |
Fair Price Momentum | 36.14 USD |
Fair Price DCF | 91.56 USD |
AMPH Dividends
No Dividends PaidAMPH Growth Ratios
Growth Correlation 3m | -69.6% |
Growth Correlation 12m | -20% |
Growth Correlation 5y | 88.4% |
CAGR 5y | 14.97% |
CAGR/Mean DD 5y | 0.86 |
Sharpe Ratio 12m | -1.06 |
Alpha | -55.58 |
Beta | 0.71 |
Volatility | 43.75% |
Current Volume | 2484.9k |
Average Volume 20d | 611.1k |
What is the price of AMPH stocks?
As of December 21, 2024, the stock is trading at USD 39.14 with a total of 2,484,940 shares traded.
Over the past week, the price has changed by -7.34%, over one month by -11.23%, over three months by -20.41% and over the past year by -33.13%.
As of December 21, 2024, the stock is trading at USD 39.14 with a total of 2,484,940 shares traded.
Over the past week, the price has changed by -7.34%, over one month by -11.23%, over three months by -20.41% and over the past year by -33.13%.
Is Amphastar P a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 84.29 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMPH as of December 2024 is 36.14. This means that AMPH is currently overvalued and has a potential downside of -7.66%.
Yes, based on ValueRay Fundamental Analyses, Amphastar P (NASDAQ:AMPH) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 84.29 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMPH as of December 2024 is 36.14. This means that AMPH is currently overvalued and has a potential downside of -7.66%.
Is AMPH a buy, sell or hold?
Amphastar P has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold AMPH.
Amphastar P has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold AMPH.
- Strong Buy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecast for AMPH stock price target?
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 39.4 in December 2025. The stock is currently trading at 39.14. This means that the stock has a potential upside of +0.54%.
According to ValueRays Forecast Model, AMPH Amphastar P will be worth about 39.4 in December 2025. The stock is currently trading at 39.14. This means that the stock has a potential upside of +0.54%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 58.2 | 48.7% |
Analysts Target Price | 69 | 76.3% |
ValueRay Target Price | 39.4 | 0.5% |